The Biliary Tumor drugs in development market research report provides comprehensive information on the therapeutics under development for Biliary Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Biliary Tumor. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Biliary Tumor and features dormant and discontinued products.
GlobalData tracks 21 drugs in development for Biliary Tumor by 20 companies/universities/institutes. The top development phase for Biliary Tumor is phase ii with nine drugs in that stage. The Biliary Tumor pipeline has 19 drugs in development by companies and two by universities/ institutes. Some of the companies in the Biliary Tumor pipeline products market are: UTC Therapeutics, Processa Pharmaceuticals and Pharma Mar.
The key targets in the Biliary Tumor pipeline products market include Receptor Tyrosine Protein Kinase ERBB 2, Programmed Cell Death Protein 1, and Protein Arginine N Methyltransferase 5.
The key mechanisms of action in the Biliary Tumor pipeline product include Programmed Cell Death Protein 1 Antagonist with two drugs in Phase II. The Biliary Tumor pipeline products include six routes of administration with the top ROA being Oral and five key molecule types in the Biliary Tumor pipeline products market including Small Molecule, and Monoclonal Antibody.
Biliary Tumor overview
Bile duct cancer, or cholangiocarcinoma, is a rare malignancy arising from malignant cells forming in the bile ducts. It presents in two main types: intrahepatic, occurring inside the liver, and extrahepatic, forming outside the liver. Extrahepatic bile duct cancer further divides into perihilar, found where the right and left bile ducts meet, and distal, located where liver and gallbladder ducts merge. Symptoms include jaundice, dark urine, abdominal pain, fever, itchy skin, nausea, vomiting, and unexplained weight loss. These signs, while indicative of bile duct cancer, may also stem from other conditions, emphasizing the importance of consulting a doctor for a thorough evaluation.
For a complete picture of Biliary Tumor’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
